Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530993 | 0.75 | MAOB (0.40) | CA12CA1CA9GAAKMT2A | |
| SCHEMBL16875695 | 0.75 | CA1 (0.39) | CA12CA1CA9GAAKMT2A | |
| SCHEMBL16875692 | 0.74 | CA12 (0.38) | CA12CA1CA9GAAKEAP1 | |
| SCHEMBL16875693 | 0.73 | KMT2A (0.35) | CA12CA1CA9KMT2AALDH1A1 | |
| SCHEMBL16875682 | 0.73 | AKR1C3 (0.36) | CA12CA1CA9KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL29229585 | 0.72 | ALDH1A1 (0.45) | CA12CA1CA9GAAKMT2A | |
| SCHEMBL529829 | 0.70 | CA12 (0.47) | CA12CA1CA9GAAKMT2A | |
| SCHEMBL458085 | 0.68 | CA12 (1.00) | CA12CA1CA9KMT2AALDH1A1 | |
| SCHEMBL317655 | 0.68 | ALB (0.49) | CA12CA1CA9GAAKMT2A | |
| SCHEMBL317764 | 0.68 | CA12 (0.42) | CA12CA1CA9KEAP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2024-06-20 | — | — | US | disclosed |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | TRANSFERT PLUS, SOCIÉTÉ EN COMMANDITE (CA) | 2024-05-16 | — | — | US | disclosed |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | TRANSFERT PLUS, S.E.C. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | THERATECHNOLOGIES INC. (CA) | 2023-02-02 | — | — | US | disclosed |
| US-20220356209-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS, S.E.C. (CA) | 2022-11-10 | — | — | US | disclosed |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | TRANSFERT PLUS, S.E.C. (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11034727-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | TRANSFERT PLUS, S.E.C. (CA) | 2021-06-15 | — | — | US | disclosed |
| US-20200392184-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | THERATECHNOLOGIES INC. (CA) | 2020-12-17 | — | — | US | disclosed |
| US-20200157151-A1 | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES | TRANSFERT PLUS, S.E.C. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC (CA) | 2017-11-16 | — | — | US | disclosed |
| US-20170281787-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | ANGIOCHEM INC (CA) | 2017-10-05 | — | — | US | disclosed |
| EP-2885318-A1 | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014026283-A1 | PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2014-02-20 | — | — | WO | disclosed |
| EP-2598522-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015691-A2 | RECOMBINANT LECTINS, BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2391216-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2391215-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | Smartcells, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088268-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392184-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, GNRHR, GRPR | CA12 3434/4885CA1 4394/4885CA9 1743/4885 |
| US-20230036041-A1 | SORTILIN BINDING CONJUGATE COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR TREATING CANCER | SORT1, NGLY1, SNX9 | CA12 2805/4885CA1 4442/4885CA9 413/4885 |
| US-20240199695-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, VIP, NPY1R | CA12 2389/4885CA1 3544/4885CA9 381/4885 |
| US-20170326233-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, SERPINA3 | CA12 734/4885CA1 629/4885CA9 1417/4885 |
| US-11034727-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | NGLY1, GNRHR, GRPR | CA12 3434/4885CA1 4394/4885CA9 1743/4885 |
| US-20240156971-A1 | METHODS AND SORTILIN BINDING CONJUGATE COMPOUNDS FOR TARGETING CANCER STEM CELLS | SORT1, CD44, SCARB1 | CA12 1468/4885CA1 3371/4885CA9 2035/4885 |
| US-20170281787-A1 | CONJUGATES INCLUDING AN ANTIBODY MOIETY, A POLYPEPTIDE THAT TRAVERSES THE BLOOD-BRAIN BARRIER, AND A CYTOTOXIN | VIP, KLKB1, ADAM17 | CA12 810/4885CA1 650/4885CA9 1438/4885 |
| US-20220000971-A1 | METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY | SORT1, FLT1, FLT4 | CA12 2092/4885CA1 4120/4885CA9 228/4885 |
| US-20220356209-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | NGLY1, VIP, NPY1R | CA12 2284/4885CA1 3469/4885CA9 263/4885 |
| US-11780882-B2 | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | NGLY1, VIP, NPY1R | CA12 2269/4885CA1 3461/4885CA9 314/4885 |
| US-20200157151-A1 | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES | VIP, TNFRSF9, TNFRSF1A | CA12 4352/4885CA1 4509/4885CA9 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.